Brief: Panbela Announces 2nd Independent Safety Review Of The Aspire Registration Clinical Trial
29/11/2023 15:58
Nov 29 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES 2ND INDEPENDENT SAFETY REVIEW OF THE
ASPIRE
REGISTRATION CLINICAL TRIAL: RECOMMENDED CONTINUATION WITH NO
TRIAL MODIFICATION
* PANBELA THERAPEUTICS INC - LOOKING FORWARD TO INTERIM
ANALYSIS
IN MID-2024
* PANBELA THERAPEUTICS INC - DSMB HAS RECOMMENDED THAT STUDY
CONTINUE WITHOUT MODIFICATION
* PANBELA THERAPEUTICS INC - NO SAFETY CONCERNS WERE
IDENTIFIED
AND DSMB'S RECOMMENDATION IS TO PROCEED WITHOUT MODIFICATION TO
ASPIRE TRIAL
Source text for Eikon: ID:nGNXLt45m
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants